Orthomimetics
Dereham
About Orthomimetics
Orthomimetics was founded in 2005 as a spin-out from the University of Cambridge and the Massachusetts Institute of Technology (MIT). Its products are based on a leading collagen biomaterials platform for the production of scaffolds for cartilage, meniscus, ligament and tendon repair. Orthomimetics’ flagship product, Chondromimetic™, is an off-the-shelf, resorbable implant for the minimally invasive repair of small osteochondral (cartilage and underlying bone) defects. The product has received European market approval (CE-Mark approval) and is close to entering the European market. Small osteochondral defects represent an important medical need that is currently not covered by TiGenix’ products. Chondromimetic™ forms an excellent fit with TiGenix’ lead product, ChondroCelect®, since both products target the same customer base in complementary indications.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $9.9M
- Funding stage: M&A
- Last round: Series A (Dec 2006)
Industries & Categories
Biotechnology, Manufacturing, Medical
Canonical: https://fsome.com/organization/orthomimetics-3421086 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.